AspergillusOne-Health: Deciphering Azole Resistance in Aspergillus Fungi Using a One Health Approach

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-09-01

Study Completion Date

2028-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

During a two year prospective study onpatients from department's hospitals and centralized by the pneumology department Nantes CH,all respiratory clinical samples will be cultivated for Aspergillus isolation (2900Aspergillusisolates) as standard care. The azole susceptibility pattern of isolates will be determined to itraconazole, voriconazole by subculture on azole- enriched medium at 35°c as primary screen and resistance confirmed by EUCAST Reference metho.In parallel, the relevance of detecting resistance (TR34 and TR46) directly in culture-negative BAL respiratory samples by a qPCR method will be studied in an attempt to reach a greater exhaustiveness of the resistance phenomeno. In case of azole-resistant isolate,patient data such as the underlying disease,date and site of Aspergillus isolation,disease classification,previous azole drug exposure,and home and work geographic allocation,occupation of the patient will be collecte. For all other aspergillus occurrences, underlying disease, previous azole drug exposure,home and work location of the patient will be collected in an attempt to identify risk factor.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PCR Based Detection of Azole Resistance in A. Fumigatus to Improve Patient Outcome.

NCT03121235

Aspergillosis, Invasive Pulmonary

COMPLETED

Aspergillosis and Humoral Alveolar Immunity by Proteomics

NCT04728763

Aspergillus Fumigatus Infection

UNKNOWN

Efflux Pump Mediated Azole Resistance in Candida Albicans

NCT03659162

Fungal Infection

UNKNOWN

PCR for Aspergillus Fumigatus in Blood and Bronchoalveolar Lavage Fluid for Monitoring Cases of Invasive Aspergillosis: What is Its Prognostic Value

NCT07313527

Invasive Pulmonary Aspergillosis

RECRUITING

Chronic Pulmonary Aspergillosis and Ambisome Aerosol with Itraconazole

NCT03656081

Chronic Pulmonary Aspergillosis

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aspergillus Fumigatus Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group control : patient without resistance

control patients with susceptible Aspergillus.

No intervention

Intervention Type OTHER

No intervention excepted data collection

Group resistant : patient without resistance

Cases are patients with resistant Aspergillus

No intervention

Intervention Type OTHER

No intervention excepted data collection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

No intervention excepted data collection

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient over 18 years of age
* Patient who has given his or her consent to participate in the study
* Patient affiliated to a social security scheme
* Patient with a respiratory sample taken between 2020 and 2023 for the retrospective cohort and from 2024 for the prospective cohort in which Aspergillus has been isolated
* Patients living in the Loire Atlantique and Vendée regions